UBS Group
SRTA

UBS Group’s Strata Critical Medical Inc SRTA Stock Holding History

UBS Group’s Portfolio SRTA Stock Details SRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Buy
293,593
+151,186
+106% +$728K ﹤0.01% 5390
2025
Q4 		$685K Sell
142,407
-91,038
-39% -$440K ﹤0.01% 5880
2025
Q3 		$1.18M Sell
233,445
-55,968
-19% -$247K ﹤0.01% 5422
2025
Q2 		$1.17M Buy
289,413
+90,098
+45% +$293K ﹤0.01% 5306
2025
Q1 		$544K Sell
199,315
-22,779
-10% -$81.7K ﹤0.01% 5784
2024
Q4 		$944K Buy
222,094
+67,865
+44% +$258K ﹤0.01% 5344
2024
Q3 		$453K Buy
154,229
+54,758
+55% +$174K ﹤0.01% 5296
2024
Q2 		$346K Sell
99,471
-2,402
-2% -$8.01K ﹤0.01% 5281
2024
Q1 		$290K Sell
101,873
-7,059
-6% -$21.8K ﹤0.01% 5592
2023
Q4 		$385K Buy
108,932
+28,566
+36% +$82K ﹤0.01% 5310
2023
Q3 		$208K Sell
80,366
-10,744
-12% -$37.7K ﹤0.01% 5342
2023
Q2 		$359K Sell
91,110
-587
-0.6% -$1.86K ﹤0.01% 5089
2023
Q1 		$310K Buy
91,697
+2,030
+2% +$8.28K ﹤0.01% 5057
2022
Q4 		$321K Sell
89,667
-9,238
-9% -$39.5K ﹤0.01% 5060
2022
Q3 		$399K Buy
98,905
+18,870
+24% +$96.9K ﹤0.01% 4534
2022
Q2 		$357K Buy
80,035
+7,336
+10% +$52.9K ﹤0.01% 4516
2022
Q1 		$618K Sell
72,699
-13,262
-15% -$93.2K ﹤0.01% 4539
2021
Q4 		$759K Sell
85,961
-9,247
-10% -$87.9K ﹤0.01% 4629
2021
Q3 		$990K Buy
95,208
+43,765
+85% +$382K ﹤0.01% 4207
2021
Q2 		$540K Sell
51,443
-18,259
-26% -$180K ﹤0.01% 4665
2021
Q1 		$717K Buy
69,702
+68,443
+5,436% +$952K ﹤0.01% 4571
2020
Q4 		$14K Buy
1,259
+689
+121% +$7.03K ﹤0.01% 7209
2020
Q3 		$6K Buy
+570
New +$5.76K ﹤0.01% 7205

Other funds holding SRTA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PLC
Pillsbury Lake Capital San Francisco, California $221M AUM
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's SRTA Position: Q1 2026 in Review

UBS Group increased its Strata Critical Medical Inc (SRTA) stake by 106% in Q1 2026, buying an estimated $728K and bringing the position to 293,593 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #5390.

UBS Group first reported a position in SRTA in Q3 2020 and has held it in 23 quarters since. 125 funds tracked by Wall St. Rank hold SRTA as of Q1 2026.

  • UBS Group held 293,593 shares of Strata Critical Medical Inc worth $1.23M as of Q1 2026.
  • UBS Group bought 151,186 Strata Critical Medical Inc shares in Q1 2026, an estimated $728K.
  • Strata Critical Medical Inc made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5390 holding.
  • UBS Group first reported a position in Strata Critical Medical Inc in Q3 2020 and has held it in 23 quarters since.
  • 125 funds tracked by Wall St. Rank held Strata Critical Medical Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.